Member Info for avctIPmatters

FYI :

"3B shall acquire 70% of the total paid-up share capital and TPE shall acquire 30% of the total paid-up share capital by 10th September 2025, and accordingly Coris shall become a subsidiary of the company as per the conditions set out in the Share Purchase agreement signed between the parties."

https://3bblackbio.com/wp-content/uploads/2025/02/Intimation-under-Reg-30-dt-28-07-2025.pdf

Avacta Diagnostics no more : Hope it works out well for Coris & LD : Guess David Wilson Avacta Commercial Director & Craig Slater COO also surplus to requirements .

---------------------------

https://3bblackbio.com/news

3B BlackBio Dx Limited3B BlackBio Dx Limited

3,963 followers3,963 followers

1h • 1 hour ago • Visible to anyone on or off LinkedIn

Follow

Coris BioConcept joins the 3B BlackBio Dx family! 🎉

We’re proud to announce that 3B BlackBio Dx Ltd., together with its subsidiary TRUPCR® Europe, has completed the acquisition of Coris BioConcept, strengthening our position in global diagnostics

Based in Gembloux, Belgium, Coris is a recognized innovator in CE‑IVD rapid lateral flow test kits for respiratory, gastro‑enteric, blood‑borne pathogens and antibiotic resistance markers. Built on a foundation of ISO 13485 quality and a newly commissioned modern facility, Coris's portfolio is a perfect complement to our PCR‑based TRUPCR® assays

🔬 This acquisition aligns with our vision to deliver a full-spectrum in‑vitro diagnostics platform, combining TRUPCR®’s highly sensitive PCR diagnostics and Coris’s point‑of‑care rapid tests to support healthcare professionals globally.

What this means for our stakeholders:

📈 Expanded diagnostics capabilities, from centralized labs to decentralized settings

🌍 Broader global reach across Europe, Asia, Africa, and beyond

💡 Enhanced IP‑rich product development across both PCR and lateral flow technologies

We are excited about the next chapter in our growth journey. A warm welcome to the Coris team—we look forward to achieving new heights together!

To know more about this, please visit https://lnkd.in/det2YCAT

hashtag#Diagnostics hashtag#InVitroDiagnostics hashtag#IVD hashtag#MolecularDiagnostics hashtag#PointOfCareTesting hashtag#LateralFlow hashtag#PCR hashtag#HealthcareInnovation hashtag#MedTech hashtag#GlobalHealth hashtag#3BBlackBioDx hashtag#TRUPCREurope hashtag#CorisBioConcept hashtag#Acquisition hashtag#AntimicrobialResistance hashtag#QualityDiagnostics

Gmcc

Courtesy Ruairidh Edwards -R & D spotlight star -

Phase one might seem to be taking ages but could actually speed up later phase commercialisation process - comprehensive clinical data is key .

Anyway Info below kind of supports what Avacta are now doing .

Might be of interest .

--------------------------

https://www.linkedin.com/in/ruairidh-edwards-4882658a/recent-activity/reactions/

------------------------------

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology

https://ascopubs.org/doi/10.1200/JCO-25-00488

------------------------

Josie Hayes PhDJosie Hayes PhD

• 3rd+Premium • 3rd+

Helping Small Pharma Turn Biomarker Uncertainty into Strategic Advantage | Biomarker Strategy Consultant | Preclinical to Phase 2 | Bioinformatics | Clinical CytogeneticistHelping Small Pharma Turn Biomarker Uncertainty into Strategic Advantage | Biomarker Strategy Consultant | Preclinical to Phase 2 | Bioinformatics | Clinical Cytogeneticist

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

Many small biotech teams treat Phase I like a safety study with some biomarker data on the side.

Completely backwards.

Phase I should be your most intensive biomarker collection period.

https://www.linkedin.com/in/ruairidh-edwards-4882658a/recent-activity/reactions/

Gmcc

Nice to see some upwards movement in AVCT market cap value : Still a way to go to get true value , however very encouraging sound bites from the company this week . Very pleased Avacta own the IP assets & secured Patent rights .

----------

This press should do no harm - hopefully new Coris buyer impressed .

"CORIS BIOCONCEPTCORIS BIOCONCEPT

2,980 followers2,980 followers

Visit website

8h • 8 hours ago • Visible to anyone on or off LinkedIn

Follow

🔬 𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗴𝗵𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗺𝘂𝗹𝘁𝗶𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝘀 𝗶𝗻 𝗔𝗹𝗴𝗲𝗿𝗶𝗮.

Today, we wanted to share this insightful work presented by Professor Bachtarzi and his team from the Central Laboratory of CHU Beni Messous during the 𝗦𝗔𝗠𝗜𝗖 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗔𝗹𝗴𝗶𝗲𝗿𝘀, highlighting their first experience with our RESIST ACINETO test.

This prospective study - conducted over seven months - demonstrates the clinical utility of a rapid immunochromatographic test to identify key carbapenemase profiles in Imipenem-Resistant Acinetobacter baumannii.

🏥 Among the 53 unique CRAB strains tested, the team was able to rapidly identify 5 distinct resistance profiles, including co-expressions, thanks to RESIST ACINETO's ability to detect OXA-23, OXA-40/58, and NDM enzymes.

✨ This first reported use of RESIST ACINETO in Algeria showcases how rapid diagnostics can effectively complement existing laboratory strategies.

Thanks to the CHU Beni Messous team for their commitment to advancing local diagnostic capacity! 🙏

hashtag#AntimicrobialResistance hashtag#Carbapenemase hashtag#RapidDiagnostics hashtag#AcinetobacterBaumannii hashtag#CorisBioConcept hashtag#RESISTACINETO hashtag#SAMIC2025 hashtag#InfectiousDiseases

Your document has finished loading

https://www.linkedin.com/feed/update/urn:li:activity:7354417135974006785/

-----------

Gmcc

New slide courtesy of X https://x.com/asininitybeyond/status/1948316528618684553/photo/1

Nice slide "FAP-EXd(AVA6103) Represents a Large Market Opportunity - FAP-EXd (AVA6103) pre|CISION® peptide

" Multiple large market opportunities for FAP-Exdinclude pancreatic cancer, gastric cancer, small cell and non-small cell lung cancer, breast cancer, among others"

Gmcc

Thanks for sharing Saint68 -

Gmcc

Good Morning David Wilson Avacta still promoting Coris they seem to have global reach for AMR products :

David Wilson likes this Page 40 https://www.yumpu.com/pt/document/read/68709074/revista-newslab-edicao-183

Nanosens Ltda.Nanosens Ltda.

157 followers157 followers

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

With national manufacture, Belgian technology and the first product on the market that meets RDC 830/23.

The RESIST-5 offers:

✔ High sensitivity and specificity

✔ Result in up to 15 minutes

✔ Ease of use and straightforward visual reading

✔ Storage at room temperature

A fast, cost-effective, and reliable solution for laboratories working on the front lines against antimicrobial resistance (AMR).

🔗 Learn more at: nanosens.com.br

---------------------

Show original

Translation settings

Nanosens Ltda.Nanosens Ltda.

157 followers157 followers

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

With national manufacture, Belgian technology and the first product on the market that meets RDC 830/23.

The RESIST-5 offers:

✔ High sensitivity and specificity

✔ Result in up to 15 minutes

✔ Ease of use and straightforward visual reading

✔ Storage at room temperature

A fast, cost-effective, and reliable solution for laboratories working on the front lines against antimicrobial resistance (AMR).

🔗 Learn more at: nanosens.com.br

Show original·

Translation settings

https://www.linkedin.com/company/nanosens-ltda/posts/?feedView=all

https://nanosens.com.br/

Nanosens Ltda.Nanosens Ltda.

157 followers157 followers

4d • 4 days ago • Visible to anyone on or off LinkedIn

Follow

Nanosens was featured in Newslab Magazine Edition 183, recognizing our performance as exclusive manufacturers of Coris BioConcept in Brazil.

We thank Newslab Magazine for the recognition and reinforce our commitment to bringing innovation and quality to the Brazilian health sector!

Read the full article through the link: https://lnkd.in/gSNjGTGb

Show original

·

Translation settings

Activate to view larger image,

No alternative text description for this image

Activate to view larger image,

like

2

3 reposts

Like

Comment

Repost

Send

Feed post number 2

Nanosens Ltda.Nanosens Ltda.

157 followers157 followers

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

With national manufacture, Belgian technology and the first product on the market that meets RDC 830/23.

The RESIST-5 offers:

✔ High sensitivity and specificity

✔ Result in up to 15 minutes

✔ Ease of use and straightforward visual reading

✔ Storage at room temperature

A fast, cost-effective, and reliable solution for laboratories working on the front lines against antimicrobial resistance (AMR).

🔗 Learn more at: nanosens.com.br

-------

Gmcc

FYI https://www.londonstockexchange.com/discover/news-and-insights/london-stock-exchange-welcomes-2025-cohort-companies-and-funds-driving-growth-green-economy

ONDO is on LSE main market also listed as Green member . Guess LSE have stricker rules than AIM on what/when companies can say & report .

Anway nice to see CFO having a day out :

-----------

Kevin WithingtonKevin Withington

• 3rd+Verified • 3rd+

Chief Financial Officer at Ondo Insurtech plcChief Financial Officer at Ondo Insurtech plc

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

Enjoyable visit to the stock exchange celebrating the green economy mark class of 2025 of which Ondo insurtech plc is a proud member alongside 101 other green companies

Thanks to Nataliya Manifold and Claire Dorrian for an excellent event

---------------------

Claire DorrianClaire Dorrian

• FollowingVerified • Following

Head of Sustainable Finance, Capital Markets and Post Trade at LSEG (London Stock Exchange Group) LSEG Women Inspired Network (WIN)Head of Sustainable Finance, Capital Markets and Post Trade at LSEG (London Stock Exchange Group) LSEG Women Inspired Network (WIN)

4d • 4 days ago • Visible to anyone on or off LinkedIn

It was a great occasion yesterday celebrating the Green Economy Mark cohort for 2025. Congratulations to each of the 101 companies and funds who represent a powerful cross-section of the green economy, from clean energy and sustainable transport to circular economy technologies and green real estate.

· The cohort includes 75 corporates and 26 closed-end funds, with 61 listed on the Main Market and 40 on AIM.

· Together, the cohort employs over 242,000 people worldwide, and the combined market capitalisation has reached a record £195 billion, a 188% increase compared to the 2020 cohort.

London Stock ExchangeLondon Stock Exchange

139,185 followers139,185 followers

4d • 4 days ago • Visible to anyone on or off LinkedIn

Follow

We were delighted to welcome the 2025 cohort of Green Economy Mark companies and funds to close the London-listed markets yesterday. The Green Economy Mark Class of 2025 is comprised of 101 companies and funds, with companies covering a broad array of activities: from clean transport and generating renewable energy, to building greener homes and pioneering circular economy technologies. The range of impact these green leaders have is equally diverse, shaping a sustainable and resilient economy of the future, and their contributions deserve to be celebrated.

https://lseg.group/4nWByyJ

hashtag#GreenEconomyMark hashtag#GreenEconomy hashtag#GEM2025

Gmcc

I certainly don't pretend to understand the science . Hopefully some correlation with what Avacta trials have demonstrated so far , hopefully they are on the right track . +TNBC etc .

Slide 16 " AVA6000 Results in Complete Regression of Large Skin Metastasis in a Patient "

https://avacta.com/wp-content/uploads/2025/03/Avacta-Corporate-Presentation_March-2025_.pdf

----------

https://x.com/MSKCancerCenter

Memorial Sloan Kettering Cancer Center

@MSKCancerCenter

·

2h

“Metastasis used to be an automatic death sentence, but that is no longer the case,” says Dr. Joan Massagué, Chief Scientific Officer at MSK.

At

@AACR

's 2025 Annual Meeting, he presented emerging insights into the biology of #metastasis and their potential to inform future cancer treatments. #AACR25 Learn more: https://bit.ly/3IPjGFL

https://www.mskcc.org/news/how-cancer-spreads-four-emerging-insights?utm_source=X&utm_medium=Organic+Social&utm_term=&utm_content=Image+of+Dr.+Massagu%C3%A9&utm_campaign=Social+Media+Posts+July+2025

-----------

"In a study published in Cancer Cell, the Massagué Lab showed that two major types of breast cancer — triple-negative breast cancer and HER2-positive breast cancer — employ distinct strategies when spreading to the brain.

Triple-negative cancers, for example, tend to spread out in sheaths around blood capillaries that infiltrate the surrounding tissue, leaving the boundary between the tumor and healthy tissue less defined. HER2-positive cancers, on the other hand, tend to form compact tumor spheroids that are more segregated and defined."

Anyway an interesting read .

gmcc

Oops simply -not simpley

Good day : Courtesy of Marty McFly thanks

Nice reminder why to stay invested - simpley put.

https://x.com/Blueberrymgmnt

This is what Avacta is all about - Consise description of Avacta science technology

------------------------------------

#AVCT has a two pillar business model:

1️⃣ Drug engine: Uses preCISION to create & license multiple tumour-activated therapies each year.

2️⃣ Platform licensing: Precision-enabled partner drugs (even failed ones) for safer, targeted use.

Scalable & repeatable.

11:15 AM · Jul 20, 2025

·

256

Views

Marty McFly

@Blueberrymgmnt

·

45m

Pillar 1️⃣: A drug engine powered by pre|CISION.

It can repeatedly generate tumour-activated therapies, ready for out-licensing.

Think of it as a biotech blueprint that can output multiple derisked assets every year.

Pipeline scale = market cap upside.

Marty McFly

@Blueberrymgmnt

·

40m

Pillar 2️⃣: Licensing its preCISION platform to partners.

It helps partners unlock the potential of existing drugs by making them truly tumour-activated with preCISION, especially those limited/failed due to toxicity.

A powerful way to extend pipelines and create new value."

Gmcc

Note Ruairidh Edwards Principal Scientist at Avacta (Therapeutics) -likes this :

Might benefit Avacta :

https://www.fda.gov/media/187589/download

"Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-cancer-drugs-use-novel-combination-determining-contribution-individual-drugs-effects

----------------------

FDA draft guidance today 👇

We are going to need combos to achieve high response rates in oncology based on the hallmarks of cancer that fuel tumors> a monotherapy targeting one biological pathway is not going to cut it!

We need to execute Whac-A-Mole with lots of therapeutic mallets targeting different biological pathways! 🔨🔨🔨🔨🔨🔨🔨🔨🔨🔨🔨🔨🔨🔨

🔖 "Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ Effects"

👉A novel combination of drugs may be considered for development when the necessity of each drug in the proposed combination is supported by a strong BIOLOGIC RATIONALE including the nonclinical characterization of each drug in the combination and early clinical evidence.

Biomarkers are important obviously 😁

👉 An investigational drug that is expected to have limited activity as monotherapy but may potentiate the treatment effect of the second drug in the combination (synergy) based on relevant nonclinical studies and/or short-term clinical studies on an established BIOMARKER

👉 The primary endpoint of a trial intended to demonstrate contribution of effect for each component of a combination may be a persuasive pharmacodynamic/response BIOMARKER that can provide direct evidence of a treatment effect for that cancer (e.g., overall response rate with duration of response information) and can be measured earlier than other clinical endpoints of importance such as progression-free (PFS) or overall survival.

👉Other endpoints such as patient-reported outcomes, or other measure of clinical outcomes and BIOMARKERS, when validated, may also be considered.

This is a great step forward 🏃‍♀️‍➡️

https://www.linkedin.com/in/ruairidh-edwards-4882658a/recent-activity/reactions/

https://www.linkedin.com/feed/update/urn:li:activity:7351280374146031616/

--------------------

Gmcc

Christina Coughin, CEO of Avacta commented:

CEO sounds confident:

"This placing for July's convertible bond repayment presents us with greater funding solution optionality, as we enter a pivotal period commercially with multiple catalysts over the coming months. I am very confident our strengthened Board and management team will ensure we are well positioned to capitalize on the multiple opportunities our pre|CISION® technology is enabling"

Gmcc

Nice little earner next few quarters for Richard Hughes : However if indeed "Long term, high net worth investors" then buys time for Avacta to extract true value from the IP assets - Well done Avacta another tick in the box

------------- .

"Richard Hughes, a Director of the Company, is an associate of Zeus as defined under the AIM Rules. Zeus is therefore a related party of the Company pursuant to the AIM Rules and the payment of a 5 per cent. commission on the value of the Placing Shares placed by Zeus, being £94,500, ("the Zeus Commission") pursuant to the terms of the Placing Agreement is deemed a related party transaction. The Directors (other than Richard Hughes who is an associate of Zeus Capital) consider, having consulted with the Company's nominated adviser Peel Hunt, that the Zeus Commission is fair and reasonable insofar as Shareholders are concerned."

Gmcc

Courtesy https://x.com/hashtag/AVCT?src=hashtag_click&f=live

-----------------------

https://www.businesswire.com/news/home/20250716186647/en/Peptide-Drug-Conjugate-Market-Research-2025-A-%241.4-Billion-Opportunity---Drug-Sales-Price-Dosage-Clinical-Trials-Insights-to-2030---ResearchAndMarkets.com

----------------

"12. Competitive Landscape

12.1 Angiochem

12.2 Avacta

12.3 Bicycle Therapeutics

12.4 Cybrexa Therapeutics

12.5 ITM Solucin

12.6 Novartis

12.7 Oncopeptides

12.8 PepGen Corporation

12.9 Soricimed Biopharma

12.10 Theratechnologies"

They seem pleased : "We're thrilled to announce the successful placement of Dr. David Liebowitz" - "the promise of revolutionizing oncology and creating new possibilities for cancer patients globally." Hidden value in Avacta IP assets .

https://www.linkedin.com/search/results/all/?heroEntityKey=urn%3Ali%3Aorganization%3A3342419&keywords=Avacta%20Therapeutics&origin=ENTITY_SEARCH_HOME_HISTORY&sid=-zB

-------------------

HarmoniaBio SearchHarmoniaBio Search

417 followers417 followers

20h • 20 hours ago • Visible to anyone on or off LinkedIn

Follow

We're thrilled to announce the successful placement of Dr. David Liebowitz as Chief Medical Officer at Avacta Therapeutics, a clinical-stage biotech company revolutionizing cancer treatment through innovative peptide drug conjugates.

Dr. Liebowitz brings exceptional expertise to lead Avacta's clinical strategy at this crucial moment. His leadership will be instrumental in advancing Avacta's revolutionary drug delivery system, which minimizes toxic side effects while maximizing therapeutic impact through tumor-specific targeting.

The alignment of exceptional leadership with transformative science remains one of the most compelling forces in biotechnology, especially when it holds the promise of revolutionizing oncology and creating new possibilities for cancer patients globally.

Congratulations to Dr. Liebowitz on this exciting new chapter, and to the entire Avacta Therapeutics team on securing such exceptional leadership and talent for their important work.

Read the full announcement here: https://lnkd.in/e-CQGzhR

hashtag#Avacta hashtag#HarmoniaBioSearch hashtag#Biotech hashtag#Oncology hashtag#ExecutiveSearch hashtag#CancerResearch

Gmcc

Good Morning - Nice coverage if not seen before :

https://www.linkedin.com/search/results/all/?heroEntityKey=urn%3Ali%3Aorganization%3A3342419&keywords=Avacta%20Therapeutics&origin=ENTITY_SEARCH_HOME_HISTORY&sid=NzN

Growth IndexGrowth Index

1,316 followers1,316 followers

3w • Edited • 3 weeks ago • Edited • Visible to anyone on or off LinkedIn

Follow

👩‍💼 👩🏽‍💼 Female-led Healthcare company in UK’s Top 10 Growth Businesses 👩‍ 👩🏽‍🦰

💉 Avacta Therapeutics has reached a formidable seventh place in Growth Index 2025, the life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. It has been led by CEO Christina Coughlin, since May 2024.

👩‍💼As one of only five female CEOs or Founders to be leading a top 100 company into this year's Growth Index, there are important lessons to be learned from her and the other four female leaders in the index.

📚 Academic Background:

Dr. Christina Coughlin is a prominent figure in the biotechnology and oncology sectors. Her background earned her M.D. and Ph.D. from the University of Pennsylvania. And completed fellowships in Hematology and Oncology at the Children's Hospital of Philadelphia.

🏢 Industry Experience:

Her career spans roles at major pharmaceutical companies, including Wyeth, Pfizer, and Novartis. She has held senior leadership positions in biotech firms such as Immunocore, Tmunity Therapeutics, and Rubius Therapeutics.

📋 Leadership Experience:

Leadership at CytoImmune Therapeutics: Before joining Avacta, she was the Chief Executive Officer of CytoImmune Therapeutics, a clinical-stage biotechnology company focused on developing novel cancer immunotherapy products.

💼Her Role at Avacta

Board Appointment: She joined Avacta's Board of Directors in 2022 as a Non-Exec Director.

🧪 Head of Research & Development: In 2024, she was appointed Head of R&D, overseeing all pre-clinical research and clinical development activities.

💊 Chief Executive Officer: Her appointment as CEO marked a significant leadership transition, leveraging her extensive experience in oncology and drug development to drive the company's growth and innovation.

📈 Dr. Coughlin's leadership is expected to play a pivotal role in advancing Avacta's mission to develop innovative, targeted cancer therapies and diagnostics.

New to Growth Index? Click link in the comments to download the latest report.

hashtag#GrowthIndex hashtag#Founders hashtag#CEOs hashtag#fastgrowth hashtag#top100 hashtag#businesses

Gmcc

If you scroll down ONDO coverage

https://www.linkedin.com/pulse/can-insurtech-fix-homeowner-insurance-matteo-carbone-oyr7f/?trackingId=C9D%2BwPtcSFaUuoDyHItfOw%3D%3D

----------

Applying this split to the average loss ratio of the market for 2018-2024 yields 15 points on the combined ratio that can be addressed with fire protection solutions, and 21 points that can be addressed with water escape prevention solutions.

Whisker Lab and Ondo, both actual members of the IoT Insurance Observatory, are at the forefront of this connect-and-protect transformation of the homeowner insurance industry.

Whisker Lab has already partnered with more than 30 US homeowners insurance carriers to offer its Ting device – a solution for preventing electrically generated fires – to their policyholders, and is already protecting a portfolio of more than one million connected homes.

Play

Ondo is instead focused on preventing and mitigating water damage. My exchange (below) with their CEO, Craig Foster, over the past weekend illustrates the results achieved so far and his vision about how insurtech can fix homeowner insurance.

Matteo: Ondo's mission is to reduce the expected losses on a homeowner insurance portfolio. Could you share the risk prevention impact you have been able to bring to your partners and the ROI of this Insurtech approach?

Craig: Absolutely. At Ondo, we quantify ROI in two core ways:

Documented Claims Savings – When LeakBot plumbers visit a home based on a leak alert, 15% of the time they find and fix a leak that is actively damaging or potentially damaging to the home. In each of those instances our plumbers create a Claims Mitigation Report which include pictures and moisture scans giving insurer partners a complete picture of the leak scenario. This gives our insurer partners the ability to quickly estimate the loss avoided, giving an immediate and tangible read on savings potential and ROI. For every dollar an insurer partner spends on LeakBot they see two to four dollars in loss savings.

Control Group Analysis – As programs scale, partners compare performance against a statistically matched control group. This allows for a rigorous actuarial view of the impact on claim frequency and severity.

This dual approach is well-established across our partner base and has been refined over years of implementation.

While most partners keep exact ROI data confidential for competitive reasons, Swedish insurer Lansforsakringar publicly reported a 45% reduction in escape-of-water claim costs. In aggregated analyses across multiple markets and cohorts, we've seen savings of up to 70%, driven by both fewer claims and materially lower severity. LeakBot tends to intercept the largest claims before they spiral - such as catching leaks spraying into crawl spaces before structural damage occurs. One US partner recently resolved such a case for under $3,000 - where the same loss could have easily exceeded $30,000 had it gone u

Phase one : (Not Canseek ) Ac-225]-PSMA-62

“[Ac-225]-PSMA-62” is a radioligand therapy being studied for the treatment of prostate cancer.

gmcc